SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

Search

Genfit

Open

BrancheGesundheitswesen

3.304 0.3

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.29

Max

3.378

Schlüsselkennzahlen

By Trading Economics

Einkommen

-59M

-29M

Verkäufe

-53M

8M

KGV

Branchendurchschnitt

111.733

50.291

Gewinnspanne

-358.75

Angestellte

180

EBITDA

-56M

-24M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+161.33% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

22. Sept. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-10M

168M

Vorheriger Eröffnungskurs

3

Vorheriger Schlusskurs

3.304

Nachrichtenstimmung

By Acuity

37%

63%

121 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Genfit Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Juni 2025, 23:49 UTC

Ergebnisse

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26. Juni 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26. Juni 2025, 21:30 UTC

Ergebnisse

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26. Juni 2025, 21:07 UTC

Ergebnisse

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26. Juni 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26. Juni 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26. Juni 2025, 23:34 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26. Juni 2025, 23:33 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26. Juni 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers Will No Longer Receive Earnings From BWP Management

26. Juni 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26. Juni 2025, 23:31 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26. Juni 2025, 23:31 UTC

Akquisitionen, Fusionen, Übernahmen

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26. Juni 2025, 23:30 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26. Juni 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26. Juni 2025, 23:19 UTC

Akquisitionen, Fusionen, Übernahmen

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26. Juni 2025, 22:06 UTC

Ergebnisse

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. Juni 2025, 21:15 UTC

Ergebnisse

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26. Juni 2025, 21:07 UTC

Ergebnisse

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. Juni 2025, 21:06 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26. Juni 2025, 21:06 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26. Juni 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26. Juni 2025, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. Juni 2025, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. Juni 2025, 20:52 UTC

Ergebnisse

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26. Juni 2025, 20:51 UTC

Ergebnisse

Correct: Nike 4Q Net $211M, Not $200M >NKE

26. Juni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. Juni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Genfit Prognose

Kursziel

By TipRanks

161.33% Vorteil

12-Monats-Prognose

Durchschnitt 8.702 EUR  161.33%

Hoch 9 EUR

Tief 8.4 EUR

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Genfit – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

3.566 / 4.12Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

121 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.